Needham & Company Maintained Buy on Medgenics (MDGN) Following Announced Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD
June 6, 2016 7:00 AM EDTPHILADELPHIA, PA -- (Marketwired) -- 06/06/16 -- (NYSE MKT: MDGN)
Collaboration with Kyowa Hakko Kirin to develop anti-LIGHT monoclonal antibody Second program from research collaboration with The Children's Hospital of Philadelphia (CHOP) Center for Applied Genomics (CAG) Data from signal finding study in Severe Pediatric Onset Inflammatory Bowel Disease patients expected in first half 2017Medgenics, Inc. (NYSE MKT: MDGN) today announced that it has entered into a collaboration with... More
